Post job

Akorn main competitors are Gilead Sciences, Cubist Pharmaceuticals, and Merck.

Competitor Summary. See how Akorn compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
  • The oldest company is Mallinckrodt, founded in 1867.
Work at Akorn?
Share your experience

Akorn vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1971
4.8
Lake Forest, IL7$682.4M2,227
1992
4.8
Lexington, MA1$926.4M873
2004
4.8
Lake Forest, IL1$4.5B19,000
1891
4.6
Kenilworth, NJ31$64.2B74,000
1997
4.7
Bothell, WA3$2.0B900
1952
4.9
Parsippany-Troy Hills, NJ6$9.3B11,300
1988
4.9
Tarrytown, NY7$14.2B9,123
1941
4.7
Kalamazoo, MI21$22.6B43,000
1992
4.9
Rockville, MD1$131.0M1,000
1931
4.2
Deerfield, IL6$10.6B48,000
1987
4.5
Foster City, CA9$28.8B11,800
1982
4.5
Amityville, NY1$232.4M200
1993
4.9
Hayward, CA1$775.8M1,257
1947
4.3
Wilmington, MA15$4.0B18,400
1977
4.3
Minneapolis, MN1$100.5M51
2007
4.4
Somerset, NJ14$4.4B14,000
2009
4.7
Fort Collins, CO2$120.0M388
1993
3.7
Union City, CA1$240,000200
1867
4.8
Hazelwood, MO5$1.0B3,400
1887
4.9
Greenville, SC3$4.4B10,220
1959
4.6
Irvine, CA1$50.0M200

Rate Akorn's competitiveness in the market.

Zippia waving zebra

Akorn salaries vs competitors

Among Akorn competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Akorn salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Akorn
$62,397$30.00-
Cubist Pharmaceuticals
$91,725$44.10-
Hospira
$64,435$30.98-
Merck
$90,328$43.43-
Seagen
$85,008$40.87-
Zoetis
$87,092$41.87-

Compare Akorn job title salaries vs competitors

CompanyHighest salaryHourly salary
Akorn
$77,871$37.44
Stryker
$102,770$49.41
Regeneron
$99,054$47.62
Cubist Pharmaceuticals
$98,668$47.44
Merck
$96,871$46.57
Zoetis
$95,192$45.77
Human Genome Sciences
$93,589$44.99
Paddock Laboratories
$91,556$44.02
Hospira
$91,303$43.90
Gilead Sciences
$90,098$43.32
Seagen
$88,427$42.51
Baxter International
$88,369$42.49
Hi-Tech Pharmacal
$85,167$40.95
Tolmar Inc
$82,814$39.81
Charles River Labs
$81,879$39.36
Axygen
$80,946$38.92
Perrigo
$80,883$38.89
Nexgen Pharma
$80,399$38.65
Catalent Pharma Solutions
$80,319$38.61
Impax Laboratories
$80,285$38.60

Do you work at Akorn?

Does Akorn effectively differentiate itself from competitors?

Akorn jobs

Akorn demographics vs competitors

Compare gender at Akorn vs competitors

Job titleMaleFemale
Charles River Labs42%58%
Merck54%46%
Akorn54%46%
Gilead Sciences56%44%
Catalent Pharma Solutions57%43%
Baxter International59%41%

Compare race at Akorn vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
61%15%11%9%4%
9.4
57%19%9%11%4%
9.9
60%16%10%9%4%
9.7
62%15%11%9%4%
9.7
44%20%8%23%6%
9.8
56%16%10%14%4%
9.8

Akorn revenue vs competitors

Akorn revenue is $682.4M. Among it's competitors, the company with the highest revenue is Merck, $64.2B . The company with the lowest revenue is Axygen, $240.0K.

Akorn and similar companies CEOs

CEOBio
​Jose E. Almeida
Baxter International

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

James C. Foster
Charles River Labs

James Clifford Foster is the chairman and chief executive officer of Charles River Laboratories, Inc., an international company that works on the drug discovery and development process. Charles River Laboratories is the world's largest breeder of animals for use in laboratory experimentation.

Daniel O’Day
Gilead Sciences

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Roger D. Dansey
Seagen

Kevin A. Lobo
Stryker

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

Juan Ramón Alaix
Zoetis

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

What employees say about Akorn's competitors

Employee reviews
profile
4.0
A zippia user wrote a review on Mar 2023
Pros of working at Akorn

Daily challenges to meet demand and keep the product moving.

Cons of working at Akorn

They closed

Akorn benefits

Medical

Is this useful?
Work at Akorn? Share your experience

Akorn competitors FAQs

Search for jobs